PL BioScience announces Distributorship Agreement with SPI PL BioScience announces Exclusive Distributorship Agreement with Summit Pharmaceuticals International (SPI) PL BioScience GmbH is proud to announce an exclusive distribution agreement for the Japanese market with Summit Pharmaceuticals International Corporation (SPI) to support local availability of Gamma-Irradiated ELAREM™ Ultimate-FD
PL BioScience announces Material Qualification Certificate from Japan's PMDA PL BioScience announces Material Qualification Certificate for ELAREM™ Ultimate-FD PLUS from Japan's PMDA PL BioScience announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has issued a Material Qualification Certificate for ELAREM™ Ultimate-FD PLUS (GMP Grade), the company’s processed cell culture
PL BioScience announces new Board Member PL BioScience announces Ole Henrik Bang-Andreasen as the newest Member of the Board PL BioScience has revealed that Ole Henrik Bang-Andreasen has been appointed to its Board of Directors, following the passing of board member Reinhard Vogt. Ole brings significant experience and
PL BioScience Reveals Fall 2025 Conferences Attendance PL BioScience announces participation in upcoming conferences this fall PL BioScience has revealed its participation in six upcoming Fall 2025 conferences. As part of its global strategy, the company will be represented in the following conferences in Asia and Europe:
PL BioScience Announces Major Site Expansion in September 2025 Key Milestone for PL BioScience as new headquarters are announced PL BioScience announced the next major step in its expansion – an upcoming move to a new 1,200 m² facility in Aachen, in September 2025. This key milestone
PL BioScience announces Strengthening of Management Team Appointment of Oliver Dick as new Chief Technology Officer PL BioScience announced the strengthening of its management team with the appointment of Oliver Dick, PhD. Oliver Dick joins the team as Chief Technology Officer, a strategic position as the company
First Artificial Human Platelet Lysate PL BioScience Raises the Bar in Cell Culture Technology with artificial HPL PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. In partnership with the Korean biotech
We are thrilled to announce a significant milestone for PL BioScience! In a recent press release, we reveal that we have successfully closed a €7.8 million Series A financing round. This Series A funding marks a pivotal moment in our company’s growth journey. This substantial infusion
The companies agree to a worldwide Human Platelet Lysate (HPL) Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements, including redirection of HPL customers from Macopharma to PL BioScience. PL BioScience GmbH, a German life science company specializing in the production and
“Cell culture with Human Platelet Lysate – Recycled blood for new medicine" Regenerative medicine is developing rapidly. And cell cultivation plays a crucial role for the development, especially in stem cell therapy. Therefore, the demand for safe cell culture media is increasing – as a basis
“Cell cultivation: Anticoagulant-free Human Platelet Lysate” About LABO Journal LABO, a German journal for laboratory technology, introduced our new product ELAREM™ Perform-FD PLUS in the article: “Cell cultivation: Anticoagulant-free Human Platelet Lysate”. The LABO journal is specialized in scientific news, inventions and updates concerning the daily lab
“We are driven by the fact that our Human Platelet Lysate accelerates the developments in the treatment of life-threatening diseases." Dr. Hatim Hemeda, CEO About GIT The German GIT Labor-Fachzeitschrift (Lab Journal) just published a company portrait about PL BioScience. The article gives insights into our vision, the
Nutrient media for the development of regenerative therapies In the latest interview at bionity.com, our CEO Dr. Hatim Hemeda talked about the history and background idea of PL BioScience to develop nutrient media for the development of regenerative therapies. As a young life science company we develop, produce
New Press Release: Sustainable Cell Culture Medium A new press release "Recently at the bench: cell culture with Human Platelet Lysate - Sustainable Cell Culture Media" in the German Laborjournal edition from December 2021 was published. Our CEO Hatim Hemeda had the opportunity to write a guest
New press release on our Human Platelet Lysate. Read the article (in German) online via: https://www.labo.de/zell-und-mikrobiologie/tierfreies-naehrmedium.htm The LABO journal is specialized in scientific news, inventions and updates concerning the daily lab routine. So, it addresses analytics and diagnostics, new lab techniques, chemistry, food, environmental influences as well as
'Accelerating research and discovery' – Human Platelet Lysate in North America 'Accelerating research and discovery'. The mission of the team at Captivate Bio perfectly fits our mission: Providing one solution for all development stages – Human Platelet Lysate. From the beginning, we saw strong synergies between our companies.
PL BioScience starts up complementary workspace at Medace The Aachen-based biotechnology company PL BioScience was founded in 2015 as a spin-off of the RWTH Aachen University, with the idea of delivering animal component-free cell culture supplements. PL BioScience has developed an advanced nutrient solution for
PL BioScience raises € 3.7 mln from Born2Grow, Brightlands Venture Partners, TechVision Fund I and more The capital will be used to expand R&D, increase sales capacity and scale up in-house production PL BioScience produces a human-based nutrient medium for growing cells, as replacement for animal-derived
Introducing our new human Platelet Lysate brand name: ELAREM™ As a university spin-off, we started manufacturing our human Platelet Lysates (hPL) back in 2015, as ‘PL Solution’ products. For more than five years, you may know our human Platelet Lysates under this name. It is time
Read in the press article from the "Aachener Zeitung" why human Platelet Lysate is still unusual but morally inoffensive PL BioScience produces human Platelet Lysate (hPL) as a cell culture supplement. This is still unusual because using the controversial Fetal Bovine Serum (FBS) for cell culture
